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Abstract— A multi-sensing platform for applications in wire-
less and batteryless monitoring of free-moving small animals
is presented in this paper. The proposed platform hosts six
sensors: four biosensors for sensing of both disease biomarkers
and therapeutic compounds, and two further sensors (T and
pH) for biosensor calibration. Electrodeposition of Multi-Walled
Carbon Nanotubes (MWCNTs) and the subsequent function-
alization with proper enzymes is used to assure sensitivity
and specificity in electrochemical biosensing. The realized
sensors are demonstrated to be capable of measuring several
parameters: lactate with a sensitivity of 77±26 µA/mM· cm2
and a limit of detection (LOD) of 4±1 µM; glucose with a
sensitivity of 63±15 µA/mM· cm2 and a LOD of 8±2 µM;
Etoposide (a well known anti-cancer agent) with a sensitivity of
0.15±0.04 mA/mM· cm2 and a LOD of 4±1 µM; Open Circuit
Potential (OCP) measurements are used on a Pt/IrOx junction
to sense pH with a sensitivity of around -75±5mV/pH; while
a Pt resistive thermal device is used to measure physiological
temperature-range with an average sensitivity of 0.108±0.001
kΩ/°C.
I. INTRODUCTION
Translational medicine makes a quite large use of mice
especially as good and low-cost models of mammalian regu-
lators function by monitoring, e.g., the ATP [1]. Monitoring
free-moving animal is an extremely good approach because
translational medicine may monitor the disease evolution in
a more natural dynamics by following the animal models in a
situation with reduced stress. Of course, batteries are not al-
lowed on board due to size constrains when dealing with very
small animals. Batteryless passive systems are easily possible
in animal monitoring because the implant does not require
any on-board power consumption [2]. On the other hand, the
use of cameras mounted on the mouse cage provides low-
cost solutions for continuous monitoring of the behavior of
free-moving mice [3]. However, active devices are definitely
required if we want to integrate biosensors on the implant
and, therefore, systems for wireless power delivery in mouse
telemetry have been proposed few years ago [4]. This new
advance opened the possibility to develop active systems
for continuous monitoring of free-moving mice even dealing
with metabolites detection. New systems have been then
proposed for monitoring of free-moving mice dealing with
blood pressure [5], body temperature and heart pulse [6];
while remotely powered detection of pH was demonstrated
too [7]. Also the possibility of multi-channel devices has
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been demonstrated though only limited to applications in
ECG acquisitions [8]. These very recent developments show
detection of bio-signals but not metabolites. For molecular
metabolites the story is quite different because it is typically
needed to involve enzymes-based biosensors that require
more complex integration of bio-membranes and electronics.
In the area of metabolism monitoring in small animals, the
most successful development is the monitoring of glucose
in mice [9], even with implants remaining in-vivo up to 56
days [10]. More recent devices have shown detection of other
endogenous metabolites (e.g., lactate, glutamate, and ATP)
[11] though not within the same sensing platform. However,
all these more recent developments still present electrical
cables through the animals’ skin [9]–[12], which allow only
limited movement in the animal cage. In 2012, a novel
system to transmit power and receive data on completely
free-moving animals has been proposed [13], and at the end
of last year the possibility of the integration with a fully
implantable and biocompatible multi-panel array sensor has
been proposed [14]. Aim of the present paper is to present
the most recent outputs toward the development of this novel
multi-array sensor platform and to demonstrate the feasibility
to detect several endogenous metabolites (e.g., glucose, lac-
tate) and drugs (e.g., etoposide (ETO), mitoxantrone (MTX),
and etodolac (ETD) together with the sensing of pH and
temperature for biosensors calibration. The biosensors were,
in some cases, then functionalized with specific enzymes to
assure specificity and MWCNT to assure high sensitivity
for lactate and glucose [15] as well as for drugs [16]. This
passive platform is tested here with laboratory equipment
meanwhile it is built to be coupled with an active and
fully implantable potentiostat [17] and with a a wireless
powering system for power and data transmission, for further
applications in implantable devices for monitoring of free-
moving mice in a cage.
II. MATERIALS AND METHODS
A. Application scenario
The fully-implantable device consists of three main build-
ing blocks: 1) a passive sensing platform, 2) integrated
circuits (ICs) to perform electrochemical measurements and
3) a coil for power supply and data transmission. Fig. 1
shows a photograph of the implantable device after the
assembly of the different components. The device in Fig. 1 is
a not-working prototype that was intended to test the biocom-
patibility of the materials used [14]. This work will present
a complete in-vitro characterization of the passive platform,
while the electronics measurements for data communication
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Fig. 1. Photograph of the implantable chip after the assembly of the
components.
and remote powering are reported in another article [18].
B. Passive Chip Microfabrication
Microfabrication was realized at the EPFL Centre of
Micronano Technology (CMI). Silicon wafers with 500 nm
of native oxide were chosen as substrate. Chip metalization
was realized by evaporation of 10 nm of Ti, followed by
100 nm of Pt. Metal passivation was made via atomic layer
deposition of Al2O3, followed by dry etching with Argon Ion
Milling. More details on the microfabrication can be found
in [14].
C. Materials
MWCNTs (∼10 nm diameter and ∼1-2 µm length) with
5% –COOH groups content, were purchased as a powder
from DropSens (Spain). MWCNTs in powder were dispersed
in a chitosan solution (0.7% w/v) pH 5 and then sonicated
for 3 h to obtain a 8 mg/ml dispersion. All experiments
were carried out in a 100 mM phosphate buffered saline
solution (PBS, pH 7.4) as supporting electrolyte. Lactate
oxidase (LOx) from Pediococcus species and glucose ox-
idase (GOx) from Aspergillus Niger were purchased from
Roche in lyophilizate powder and dissolved in a 100 mM
PBS (pH 7.4). Lithium L-lactate and D-(+)-glucose (Sigma-
Aldrich, Switzerland) in powder and dissolved in in PBS.
The drugs ETO, MTX and ETD purchased as a powder
(Sigma-Aldrich) were dissolved in Dimethyl sulfoxide due
to their low solubility in water. For the pH sensor, a solution
of Iridium(IV) chloride hydrate (99.9% metals basis, from
Sigma Aldrich), H2O2 (30%), oxalic acid dihydrate (98%,
from Sigma Aldrich), and potassium carbonate anhydrous
(99%, from Alfa Aesar) was prepared for the deposition of
the Iridium Oxide film (IrOx), as described in [19].
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Fig. 2. Calibration line of lactate detection in CA (at a fix potential of +650
mV) after functionalization with MWCNTs and LOx. Error bars correspond
to the standard deviation for 3 different measurements (confidence interval
95.4%).
D. Electrode preparation and functionalization
For the detection of lactate and glucose in chronoam-
perometry (CA), working electrodes were functionalized by
electrodeposition of a chitosan/MWCNT dispersion 8 mg/ml
as described in [14]. For glucose and lactate measurements,
we used working electrodes (WEs) with a diameter of 500
µm and 1.2 mm, respectively. A 33 mg/ml solution of
LOx, or, alternatively, a 15 mg/ml solution of GOx, was
drop cast on some working electrodes and stored overnight
at 4°C. For the measurements in the presence of drugs
with cyclic voltammetry (CV), the electrodes were used
without modifications. For the pH sensor, we used a working
electrode of 300 µm diameter. A layer of IrOx was created
on the electrode surface by applying a constant current of
0.94 µA for 500 s. After 2 days of stabilization in PBS pH
7.4 to reduce the potential drift, the electrodes were tested
for pH sensing. All the samples were freshly prepared and
used the same day. When not in use, electrodes were stored
at 4°C.
E. Electrochemical Measurements
To test the passive sensing platform, electrochemical mea-
surements were performed using an Autolab electrochemical
workstation (Metrohm, Switzerland). Electrodes were tested
for lactate and glucose sensitivity with CA at +650 mV.
The sensors were first dipped in a 100 mM PBS solution
(pH 7.4), under stirring conditions, then conditioned for 1
h at +650 mV and then tested against repeated injections
of lactate 25 µM, or glucose 50 µM. CV was used to
identify the oxidation/reduction peaks of ETO, MTX and
ETD. CV was performed at room temperature under aerobic
conditions by applying a triangular waveform voltage in
the range between -700 mV and +700 mV vs. Pt and
a scan rate of 20 mV/s. After an initial conditioning in
PBS, which consists of 30’ of continuous cycling, drops
of 400 µl of ETO or MTX solutions were added at the
right concentration. pH was computed averaging the open
circuit potential (OCP) by continuously changing the pH of
the buffer solution by adding an acid or a basic solution
(HCl and NaOH, respectively). The pH was monitored by
means of an external pH meter (from VWR). An external
reference electrode (double junction in Ag|AgCl) was used in
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Fig. 3. Calibration line of glucose detection in CA (at a fix potential of +650
mV) after functionalization with MWCNTs and GOx. Error bars correspond
to the standard deviation for 3 different measurements (confidence interval
95.4%).
2021
0.6
0.4
0.2
0.0
-0.2
-0.4
-0.6
C
u
rr
e
n
t 
(µ
A
)
6004002000-200-400-600
Potential (mV)
 PBS
 MTX 200µM
 ETO 200µM
 ETD 200µM
Fig. 4. Cyclic voltammograms of a bare electrode in PBS, in the presence
of MTX 200µM, ETO 200µM or ETD 200µM.
order to have stable and reproducible measurements. For the
temperature sensor, a Fluke 87V Industrial multimeter (by
Fluke) was connected to our platform to measure the changes
in resistivity. Sensitivity and limit of detection (LOD) are the
key parameter used to evaluate the sensing performances.
Sensitivity per unit area was computed from the slope of
the straight line obtained by plotting the current increases
vs. glucose, lactate or drug concentration. The LOD was
computed as three times the signal-to-noise ratio according
to the expression LOD = k δiS , where δi is the standard
deviation of the blank measurements, S is the sensitivity, and
k is a parameter accounting for the confidence level (k = 1,
2, or 3 corresponds to 68.2%, 95.4%, or 99.6% of statistical
confidence) [20].
III. RESULTS AND DISCUSSION
A. Measurements of metabolites and anti-cancer drugs
After the electrodeposition of MWCNTs in chitosan and
the functionalization of the WE with the enzyme, electrodes
were tested for lactate and for glucose sensitivity with CA at
+650 mV. The CA measurements at +650 mV for lactate and
glucose are reported in Fig. 2 and Fig. 3, respectively. The
arrows correspond to repeated injections of lactate 25µM or
glucose 50 µM, respectively. Well-defined current steps are
visible every further injection. The calibration lines reported
in the insets of Fig. 2 and Fig. 3 are calculated from the
evaluation of the current steps, by measuring the difference
between the reached current value and the baseline. For
lactate we obtained a sensitivity of 77±26 µA/mM· cm2
and a LOD of 4±1 µM, while for glucose we obtained a
sensitivity of 63±15 µA/mM· cm2 and a LOD of 8±2 µM,
which fits with many clinical applications [21]. Calibration
of glucose and lactate at higher physiological concentrations
will require the adoption of a system of membranes, as
reported in [22], and it will be the object of our future
investigations. However, with our sensing platform, we can
monitor many other metabolites of clinical interest (e.g.
glutamate, ATP), by changing the enzyme.
The anti-cancer drugs ETO and MTX, and the anti-
inflammatory drug ETD were monitored with CV. CV has
been widely used to detect electroactive drugs in biological
fluids [23]. As reported in previous studies [24]–[26], ETO,
MTX and ETD are electro-active compounds that give in
CV well-defined oxidation peaks in the potential window
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Fig. 5. Calibration curve for ETO within the physiological range in
PBS, obtained in CV. Error bars correspond to the standard deviation for
4 different measurements (confidence interval 95.4%). The inset shows the
oxidation peak currents increasing with the drug concentration.
between +100 mV and +700 mV. Fig. 4 shows the cyclic
voltammograms for a bare electrode (500 µm diameter) in
PBS or in the presence of 200 µM MTX, or 200 µM ETO or
200 µM ETD. According to literature, the voltammograms
show two defined oxidation peaks for ETO (at +200 mV and
+500 mV vs. Pt), two oxidation peaks for MTX (at +250 mV
and +450 mV vs. Pt), and an oxidation peak for ETD (at
+350 mV vs. Pt). With bare electrodes, we also performed
CV measurements to calibrate the sensors for ETO within
the therapeutic range. Fig. 5 shows the dependence of the
peak current on ETO concentrations. The y-axis values are
the peak values of the current peaks centered at +500 mV.
The inset in Fig. 5 shows the linear increase in current of
the oxidation peaks at various ETO concentrations, with a
sensitivity of 0.15±0.04 mA/mM· cm2 and a LOD of 4±1
µM, which fits ETO therapeutic range (33.9-101.9, [27]).
These results prove that the sensing platform is capable to
monitor drugs and metabolites within their therapeutic or
physiological ranges.
B. Temperature sensor
The temperature sensor is a resistive thermal device (RTD)
that consists of a Pt wire of 4 µm width and 93 mm length,
with an average resistivity of 34 kΩ at 20°C. We chose Pt
since it is commonly used for resistive thermal devices and
because, among other metals Pt represents the best trade-
off between linear behavior, higher metal resistivity and
biocompatibility [28]. Fig. 6 shows the response of the Pt-
RTD upon different temperatures in PBS. The temperature
was first increased from 35°C to 42°C (forward scan) and
then was inversely changed (backward scan), showing a
linear behavior with an average sensitivity of 0.108±0.001
kΩ/°C, which is compatible with the theoretical value of
0.13 kΩ/°C (calculated from the temperature coefficient of
resistivity for Pt, α = 0.00385°C−1).
C. pH sensor
IrOx is a well-known biocompatible material already used
in the creation of implantable electrodes [19]. The OCP of
an IrOx film changes in a predictable manner according to
the pH of the solution. Fig. 7 shows the calibration of the
pH sensor measured in the pH range from 5 to 9. The pH
of the buffer solution was continuously monitored with an
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Fig. 6. Calibration curve for the temperature sensor. Error bars correspond
to the standard deviation for 9 different measurements (confidence interval
95.4%).
external pH meter and the corresponding OCP was measured
for the forward scan (pH from 5 to 9) and for the backward
scan (pH from 9 to 5). In the considered range, the potential
changes linearly with increasing pH, with a sensitivity of -
74±3 mV/pH for the forward scan, and -75±5 mV/pH for
the backward scan. Our sensor with the IrOx film showed a
near super-Nernstian response with sensitivity values similar
to the ones reported in [19].
IV. CONCLUSIONS
Aim of the present paper was to present the most advanced
developments of a novel multi-array sensor platform for
further applications in monitoring of free-moving mice. The
paper demonstrated the feasibility of the multi-panel platform
for acquiring data among several endogenous metabolites
related to animal metabolism as well as several exogenous
compounds, typically therapeutic drugs. The platform also
demonstrated the reliability of the acquired data by hosting
sensors for data calibration. The detection of glucose, lactate,
ETO, MTX, and ETD is shown as proof of the platform
capability for metabolism monitoring, while the detection
of pH and temperature is shown as proof of biosensors
calibration. The passive sensing platform presented in this
work is built to be integrated into a fully-implantable device
for further applications in monitoring of mice that are free
to move in a cage. In particular, the device will be used to
monitor concentrations of drugs and disease biomarkers in
interstitial tissues of very small animals.
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